How I treat monoclonal gammopathy of renal significance (MGRS)
| Autor: | Fermand, Jean-Paul, Bridoux, Franck, Kyle, Robert A, Kastritis, Efstathios, Weiss, Brendan M, Cook, Mark A, Drayson, Mark T, Dispenzieri, Angela, Leung, Nelson, Renseigné, Non |
|---|---|
| Přispěvatelé: | Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Service de néphrologie - hémodialyse et transplantation rénale, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU) |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Pathology
medicine.medical_specialty MESH: Cryoglobulinemia Immunology 030232 urology & nephrology Paraproteinemias Biochemistry Immunoglobulin Light-chain Amyloidosis 03 medical and health sciences 0302 clinical medicine MESH: Paraproteinemias MESH: B-Lymphocytes medicine Humans MESH: Amyloidosis Kidney transplantation Multiple myeloma MESH: Fanconi Syndrome Kidney B-Lymphocytes MESH: Kidney Diseases MESH: Humans business.industry Cell Biology Hematology Amyloidosis medicine.disease Fanconi Syndrome 3. Good health medicine.anatomical_structure Cryoglobulinemia 030220 oncology & carcinogenesis Monoclonal [SDV.IMM]Life Sciences [q-bio]/Immunology Kidney Diseases business Monoclonal gammopathy of undetermined significance Monoclonal Immunoglobulin Deposition Disease Kidney disease |
| Zdroj: | Blood Blood, American Society of Hematology, 2013, 122 (22), pp.3583-90. ⟨10.1182/blood-2013-05-495929⟩ |
| ISSN: | 0006-4971 1528-0020 |
| DOI: | 10.1182/blood-2013-05-495929⟩ |
| Popis: | Recently, the term monoclonal gammopathy of renal significance (MGRS) was introduced to distinguish monoclonal gammopathies that result in the development of kidney disease from those that are benign. By definition, patients with MGRS have B-cell clones that do not meet the definition of multiple myeloma or lymphoma. Nevertheless, these clones produce monoclonal proteins that are capable of injuring the kidney resulting in permanent damage. Except for immunoglobulin light chain amyloidosis with heart involvement in which death can be rapid, treatment of MGRS is often indicated more to preserve kidney function and prevent recurrence after kidney transplantation rather than the prolongation of life. Clinical trials are rare for MGRS-related kidney diseases, except in immunoglobulin light chain amyloidosis. Treatment recommendations are therefore based on the clinical data obtained from treatment of the clonal disorder in its malignant state. The establishment of these treatment recommendations is important until data can be obtained by clinical trials of MGRS-related kidney diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|